SecBot SecBot
8-K ·Filed Jul 14, 2026

SNDX

Syndax Pharmaceuticals Inc
BULLISH
Impact 7/10
Horizonmonths Processed4mo ago SEC0001193125-26-302608
8-K context-dependent: Items 8.01
Actionable Insight ▲ Bullish

Key catalysts to watch: Phase 2 axatilimab data in IPF and cGVHD (both 4Q26), revumenib proof-of-principle trial initiation in MF (4Q26), and IND filings for SNDX-4321 (YE 2026) and SNDX-62122 (2027). The pipeline expansion into NSCLC and MF opens new blockbuster opportunities but adds clinical and regulatory risk. Monitor enrollment timelines and early safety/efficacy signals from the MF proof-of-principle trial.

DirectionBullish
Confidencehigh
Horizonmonths

Drugs in focus

SNDX drug pipeline →

Niktimvo

▲ Bullish Named in this 8-K
Impact
Phase
Approved
Time to market
Already approved and commercially launched (FDA approved August 2024)
Next catalyst
None dated

What to watchNiktimvo's commercial trajectory is the primary value driver for SNDX on this drug. Watch Q2/Q3 2026 net revenue prints for signs of continued ramp ($151.6M FY2025 annualizing to ~$220M in Q1 2026). The Phase 2 IPF readout in Q4 2026 is an important optionality catalyst that could open a much larger market, but comes with clinical risk. The $250M convertible note issued June 2026 introduces modest dilution overhang (~8-10% of shares outstanding).

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$24.13
T+0 close · Jul 14, 2026 · via day close
Latest settled
−29.42%
T+60 · $17.03
Vs SPY
−32.80%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 14 $24.13entry
  2. T+1 · 4mo ago −2.53%α −2.92% · $23.52
  3. T+5 · 4mo ago −7.63%α −6.33% · $22.29
  4. T+20 · 3mo ago −15.91%α −18.41% · $20.29
  5. T+60 · 6w ago −29.42%α −32.80% · $17.03
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Syndax held an R&D event unveiling two new pipeline assets: SNDX-4321, a mutant-selective allosteric EGFR inhibitor for NSCLC, and SNDX-62122, a next-generation menin inhibitor for myelofibrosis. The company also highlighted upcoming Phase 2 data readouts for axatilimab in IPF (4Q26) and axatilimab + ruxolitinib in cGVHD (4Q26), and reiterated that Revuforj and Niktimvo are annualizing at ~$200M combined as of 1Q26. No financial results were reported; the filing is a strategic pipeline update.

Key Facts

  • Unveiled SNDX-4321, a mutant-selective allosteric EGFR inhibitor for NSCLC; IND submission expected by YE 2026, Phase 1 in 2027.
  • Unveiled SNDX-62122, a next-generation menin inhibitor for myelofibrosis; IND and Phase 1 expected in 2027.
  • Phase 1/2 proof-of-principle trial of revumenib in myelofibrosis expected to initiate in 4Q26 with initial data in 2H27.
  • Phase 2 MAXPIRe trial of axatilimab in IPF on track for topline data in 4Q26.
  • Phase 2 axatilimab + ruxolitinib data in cGVHD expected 4Q26.
  • Revuforj and Niktimvo combined annualizing at ~$200M as of 1Q26.
  • Company expects to have at least 4 innovative assets in the clinic by 2027.
  • SNDX-4321 is an externally developed molecule with exclusive worldwide license; SNDX-62122 is internally developed and wholly owned.

Financial Impact

No financial results reported. Revuforj and Niktimvo combined annualizing at ~$200M as of 1Q26. Company states it is fully funded to advance late-stage trials and pipeline assets.

Risk Factors

  • All pipeline assets are preclinical or early-stage; clinical failure risk is high.
  • SNDX-4321 faces competition from multiple 4th-gen EGFR inhibitors and bispecific antibodies in development.
  • Revumenib MF trial is proof-of-principle; clinical translation of preclinical data is uncertain.
  • No financial guidance or revenue figures beyond the ~$200M annualization rate were provided.
  • Reliance on partnerships (MPN-RC consortium, Incyte-led trials) introduces execution dependency.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-302608
Document: sndx-20260714.htm0001193125-26-302608
Document: sndx-ex99_1.htm0001193125-26-302608
Document: 0001193125-26-302608-index-headers.html0001193125-26-302608
Document: 0001193125-26-302608-index.html0001193125-26-302608
Document: 0001193125-26-302608.txt0001193125-26-302608

Track record

16 reports on SNDX

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 12, 20264d ago 3 Neutral 1/10 Entry $9.45 Now $9.13 −3.39% settles Feb 11
  2. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $9.49 Now $9.13 −3.79% settles Feb 8
  3. Nov 9, 20267d ago Press Release Neutral 2/10 Entry $9.49 Now $9.13 −3.79% settles Feb 8
  4. Nov 2, 202614d ago 8-K Neutral 5/10 No price data
  5. Nov 2, 202614d ago Press Release Neutral 2/10 No price data
  6. Nov 2, 202614d ago Press Release Neutral 5/10 Entry $14.29 Now $9.13 −36.11% settles Feb 1
  7. Oct 29, 202618d ago 144 Neutral 2/10 Entry $13.65 Now $9.13 −33.11% settles Jan 28
  8. Jul 14, 202617w ago 8-K Bullish 7/10 Viewing Entry $24.13 to $17.03 Now $9.13 −62.16% ▼ −29.42% −32.80% vs SPY
  9. Jul 1, 202619w ago Press Release Neutral 2/10 Entry $21.82 to $18.20 Now $9.13 −58.16% ▼ −16.59% −20.16% vs SPY
  10. Jun 11, 202622w ago Press Release Bullish 7/10 Entry $17.91 to $20.56 Now $9.13 −49.02% ▲ +14.80% +10.40% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens in 7h 17m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 14, 2026